Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 1/20 | 0.46 |
| ▸ | MAPKAPK2 | P49137 | 5/20 | 0.46 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.46 |
| ▸ | AR | P10275 | 2/20 | 0.45 |
| ▸ | AAK1 | Q2M2I8 | 4/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.44 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.44 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.43 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16052482 | 0.82 | SMO (0.43) | — | |
| SCHEMBL17457689 | 0.82 | CYP17A1 (0.46) | MAPKAPK2AAK1MAP4K4CYP17A1SREBF2 | |
| SCHEMBL30252123 | 0.82 | CYP17A1 (0.46) | MAPKAPK2AAK1MAP4K4CYP17A1SREBF2 | |
| SCHEMBL23583284 | 0.80 | FGFR4 (0.44) | MAPKAPK2EGLN2ARAAK1 | |
| SCHEMBL14775090 | 0.78 | SYK (0.50) | TTKMAPKAPK2EGLN2MAP4K4CYP17A1 | |
| SCHEMBL4301854 | 0.77 | MAP4K4 (0.56) | MAPKAPK2EGLN2AAK1MAP4K4CYP17A1 | |
| SCHEMBL29223830 | 0.76 | CYP17A1 (0.52) | MAPKAPK2MAP4K4CYP17A1SREBF2PSMB8 | |
| SCHEMBL2242578 | 0.75 | CYP17A1 (0.48) | TTKMAPKAPK2EGLN2MAP4K4CYP17A1 | |
| SCHEMBL6164774 | 0.73 | TTK (0.55) | TTKEGLN2ARMAP4K4CYP17A1 | |
| SCHEMBL27669003 | 0.73 | EGLN2 (0.62) | TTKEGLN2ARMAP4K4CYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4147700-A1 | N-(4-(AZAINDAZOL-6-YL)-PHENYL)-SULFONAMIDES FOR USE IN THE TREATMENT OF SICKLE CELL DISEASE | LQT Therapeutics Inc. (CA) | 2023-03-15 | — | — | EP | disclosed |
| US-9718825-B2 | N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides and their use as pharmaceuticals | SANOFI (FR) | 2017-08-01 | — | — | US | disclosed |
| EP-2970259-B1 | N-(4-(AZAINDAZOL-6-YL)-PHENYL)-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2016-12-21 | — | — | EP | disclosed |
| US-20160024097-A1 | N-(4-(AZAINDAZOL-6-YL)-PHENYL)-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2016-01-28 | — | — | US | disclosed |
| EP-2970259-A1 | N-(4-(AZAINDAZOL-6-YL)-PHENYL)-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014140065-A1 | N-(4-(AZAINDAZOL-6-YL)-PHENYL)-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024097-A1 | N-(4-(AZAINDAZOL-6-YL)-PHENYL)-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS | SGK1, SGK3, SGK2 | TTK 372/4885MAPKAPK2 176/4885EGLN2 4158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.